SG Americas Securities LLC Sells 60,964 Shares of Apogee Therapeutics Inc. $APGE

SG Americas Securities LLC lessened its holdings in Apogee Therapeutics Inc. (NASDAQ:APGE) by 45.4% during the fourth quarter, HoldingsChannel reports. The firm owned 73,262 shares of the company’s stock after selling 60,964 shares during the quarter. SG Americas Securities LLC’s holdings in Apogee Therapeutics were worth $5,530,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. ANTIPODES PARTNERS Ltd raised its holdings in shares of Apogee Therapeutics by 41.2% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock worth $33,000 after buying an additional 246 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Apogee Therapeutics in the third quarter valued at about $96,000. BNP Paribas Financial Markets grew its position in Apogee Therapeutics by 34.7% in the second quarter. BNP Paribas Financial Markets now owns 3,649 shares of the company’s stock valued at $158,000 after acquiring an additional 941 shares during the last quarter. E Fund Management Co. Ltd. bought a new position in Apogee Therapeutics in the second quarter valued at about $204,000. Finally, Optimize Financial Inc acquired a new position in Apogee Therapeutics during the second quarter worth about $229,000. Institutional investors own 79.04% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on APGE shares. Deutsche Bank Aktiengesellschaft started coverage on shares of Apogee Therapeutics in a report on Tuesday, December 9th. They issued a “buy” rating and a $103.00 target price for the company. Canaccord Genuity Group upped their price objective on shares of Apogee Therapeutics from $89.00 to $130.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Mizuho increased their price objective on shares of Apogee Therapeutics from $105.00 to $110.00 and gave the company an “outperform” rating in a research note on Monday. BTIG Research restated a “buy” rating and issued a $137.00 target price on shares of Apogee Therapeutics in a research report on Monday, March 23rd. Finally, Stifel Nicolaus set a $133.00 target price on shares of Apogee Therapeutics in a research note on Tuesday, January 6th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Apogee Therapeutics has an average rating of “Moderate Buy” and an average target price of $110.79.

Insider Buying and Selling at Apogee Therapeutics

In related news, Director Fairmount Funds Management Llc sold 1,750,000 shares of the business’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $76.30, for a total value of $133,525,000.00. Following the sale, the director owned 298,647 shares of the company’s stock, valued at $22,786,766.10. The trade was a 85.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Michael Thomas Henderson sold 20,000 shares of the stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $74.78, for a total value of $1,495,600.00. Following the completion of the sale, the chief executive officer owned 1,152,987 shares of the company’s stock, valued at $86,220,367.86. The trade was a 1.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 1,839,700 shares of company stock worth $140,118,083. 42.77% of the stock is currently owned by company insiders.

Apogee Therapeutics Trading Up 0.1%

NASDAQ:APGE opened at $84.24 on Thursday. The stock has a market cap of $5.85 billion, a P/E ratio of -19.96 and a beta of 1.39. The stock’s 50-day moving average is $71.03 and its 200-day moving average is $65.55. Apogee Therapeutics Inc. has a 1-year low of $26.20 and a 1-year high of $85.94.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($1.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.02. As a group, equities analysts forecast that Apogee Therapeutics Inc. will post -3.09 EPS for the current year.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.